

2002028694



162162

06 MAY 2002

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
14 June 2001 (14.06.2001)

PCT

(10) International Publication Number
WO 01/42195 A1(51) International Patent Classification⁷: C07C 237/06,
229/52, C07D 213/80, A61K 31/44, 31/24, A61P 3/04,
3/10(74) Agent: LEAROYD, Stephanie, Anne; Glaxo Wellcome
plc, Glaxo Wellcome House, Berkeley Avenue, Greenford,
Middlesex UB6 0NN (GB).

(21) International Application Number: PCT/GB00/04697

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 8 December 2000 (08.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9929297.1 11 December 1999 (11.12.1999) GB(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): LAWRENCE, Ron-
nie, Maxwell [AU/GB]; Glaxo Wellcome plc, Gunnels
Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).
MILLAR, Alan [US/US]; Glaxo Wellcome Inc., Five
Moore Drive, Research Triangle Park, NC 27709 (US).

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

ACTION

(54) Title: PROCESS FOR THE PREPARATION OF ARYLETHANOLAMINE DERIVATIVES HAVING AN ANTI-OBESITY
AND ANTI-DIABETIC PROPERTIES

(57) Abstract: A process for the preparation of a compound of Formula (IA) or a pharmaceutically acceptable salt thereof: wherein R¹ is an aryl, pyridyl, thiazolyl, phenoxyethyl, or pyrimidyl group, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, C₁₋₆alkoxy, C₁₋₆alkyl, hydroxymethyl, trifluoromethyl, -NR⁶R⁶, and -NHSO₂R⁶, where each R⁶ is independently hydrogen or C₁₋₆alkyl; R² is hydrogen or C₁₋₆alkyl; R³ is CO₂R⁷ where R⁷ is hydrogen or C₁₋₆alkyl; R⁴ and R⁵ are independently hydrogen, C₁₋₆alkyl, or -CO₂C₁₋₆alkyl; and Y is N or CH comprising the step of preparing a diamide of Formula (II) or a pharmaceutically acceptable salt thereof: wherein R¹ is an aryl, pyridyl, thiazolyl, phenoxyethyl, or pyrimidyl group, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, C₁₋₆alkoxy, C₁₋₆alkyl, hydroxymethyl, trifluoromethyl, -NR⁶R⁶, and -NHSO₂R⁶, where each R⁶ is independently hydrogen or C₁₋₆alkyl; R² is hydrogen or C₁₋₆alkyl; R³ is CO₂R⁷ where R⁷ is C₁₋₆alkyl; R⁴ and R⁵ are independently hydrogen, C₁₋₆alkyl, -CO₂C₁₋₆alkyl; and Y is N or CH.

WO 01/42195 A1